Non-invasive methods for the assessment of liver fibrosis and steatosis are replacing invasive liver biopsy due to patient wariness and the low but ever-present morbidity of biopsies. The use of non-invasive markers is also increasing because clinical questions concerning the presence or absence of steatosis, fibrosis and cirrhosis as well as treatment monitoring and follow-up can be sufficiently answered by these tests and procedures. Today, despite the dogma of the biopsy being the gold standard, the use of non-invasive liver fibrosis detection vastly outnumbers biopsies in chronic liver diseases. Non-invasive tests have problems in discriminating accurately between early stages of fibrosis, i.e., F0-F2. Notwithstanding, non-invasive markers can be used as it primarily relevant to discriminate between early stages and advanced fibrosis in clinical practice.
In addition, non-invasive tests carry the potential of being used as screening tools in population-based studies and can detect fibrosis even in individuals with normal liver function tests. Non-invasive markers should be able to reliably identify liver cirrhosis in order to initiate further diagnostic procedures to exclude portal hypertension and to intensify surveillance strategies. Non-invasive strategies are also warranted for monitoring the disease while on therapy and ideally document the regression of fibrosis during follow-up.
Non-invasiveness for the detection of fibrosis has become reality in clinical practice and has been approved for clinical studies but for hepatologists fibrosis assessment is only one puzzle piece and more information is needed. Other endemic conditions such as fatty liver disease with or without inflammatory changes and or fibrosis increase the need for other non-invasive tests that also provide information on hepatic fat contents and inflammation. Whereas ultrasound-based methods such as the controlled attenuation parameter (CAP) can be used for the rapid and easy assessment of steatosis, specific non-invasive test to classify the mode and extend of inflammation in the liver are still missing.
With most experts agreeing that non-invasive techniques do not replace liver biopsies completely, they have reduced the number of biopsies substantially (Leroy 2007, Pinzani 2005, Sebastiani 2006). Hence, the clinical question remains: Will the information change my practice or advice? Recently three major guidelines have been published on the use of elastography and other methods for non-invasive assessment of liver fibrosis, which are recommended for further reading:
This chapter reviews non-invasive (serum markers and liver stiffness measurement) markers of liver fibrosis as well as fatty liver disease and aims to illustrate what is relevant in clinical practice.
Liver fibrosis is characterised by the loss of hepatocytes, destruction of hepatic (micro)architecture, proliferation of hepatic (myo)fibroblasts, and excess deposition of extracellular matrix (Friedman 2008). The final stage of liver fibrosis (cirrhosis) may result in insufficient detoxification, portal hypertension, renal and pulmonary failure and hepatocellular carcinoma, and is associated with excess mortality. Liver cirrhosis is the common end-stage of chronic liver diseases such as chronic viral hepatitis, non-alcoholic and alcoholic liver diseases as well as autoimmune and metabolic liver diseases. The mechanisms of fibrogenesis in all aetiologies share certain aspects but differ in detail. Consequently, the non-invasive assessment of liver fibrosis also varies between diseases.
A key feature of hepatic fibrosis is the activation and proliferation of fibroblasts and hepatic stellate cells. Chronic liver injury leads to activation of these cells, which become contractile, produce the extracellular matrix components and secrete inflammatory and profibrotic cytokines and chemokines such as transforming growth factor. The activation of these cells is believed to represent the key event in hepatic fibrogenesis (Friedman 2008). Hepatic stellate cell activation depends on signalling by Kupffer cells, endothelial cells, hepatocytes, and platelets. The deposition of the extracellular matrix is constantly opposed by the degradation of these proteins. In progressive liver fibrosis, this balance is skewed in favour of excess extracellular matrix deposition. Matrix metalloproteinases and their regulators (tissue inhibitors of metalloproteinases, TIMPs) control matrix deposition and degradation.
Liver biopsy may be obtained via different routes (Table 1). The most common is the ultrasound-guided percutaneous biopsy.
||Terjung 2003, van der Poorten 2006, Myers 2008, Chi 2017|
||Cholongitas 2006, Wolska-Krawczyk 2013|
||Helmreich-Becker 2003, Denzer 2007|
The quality and reliability of fibrosis staging via histopathological assessment of liver biopsy specimens depends largely on the size of the specimen and the number of portal fields. The biopsy should be at least 20-25 mm long and more than 11 portal tracts should be visible (Bedossa 2003, Chologitas 2006, Rousselet 2005). However, in daily practice these requirements may not be easy to achieve; and even if a large enough biopsy is acquired, the specimen only reflects about 1/50,000 of the whole liver.
Thus, liver biopsies are particularly prone to sampling errors and may – like non-invasive markers – have difficulties in discriminating between adjacent stages of fibrosis (i.e., F1 vs. F2 or F2 vs. F3). Discrepancies of more than one stage are rare (Regev 2002, Siddique 2003, Skripenova 2007). Intra- and inter-observer variability may be unaffected by specimen sizes but can lead to discrepancies in up to 20% of cases, even if one stage difference between estimates is accepted (Gronbaek 2002, Petz 2003). Standardised automated staging using deep learning algorithms may improve diagnostic accuracy (Yu 2018).
There is a wide variability in the use of other staging systems in patients with chronic viral hepatitis. In Germany, current guidelines recommend the Desmet & Scheuer staging system (Supplementary Table 1) (Batts 1995, Desmet 1994, French METAVIR Cooperative Study Group 1994, Ishak 1995, Knodell 1981, Schirmacher 2004).
|Staging System||Fibrosis stages||Remarks|
|METAVIR||F0, F1, F2, F3, F4||Best evaluated in HCV fibrosis||French METAVIR Cooperative Study Group 1994|
|Knodell||F0, F1, F3, F4||No intermediate stage||Knodell 1981|
|Desmet & Scheuer||Analogous to METAVIR||Recommended by the German guidelines for the assessment of liver fibrosis||Desmet 1994, Schirmacher 2004|
|Batts & Ludwig||Similar to METAVIR||Batts 1995|
|Ishak||F0, F1, F2, F3, F4, F5, F6||Ishak 1995|
Liver fibrosis develops as a continuous process rather than in a stepwise manner. Thus, so-called surrogate markers, which are also continuous variables, may provide more precise information. Surrogate markers can be subdivided into two groups (Table 2):
Direct markers reflect changes in the content of extracellular matrix proteins (such as collagen) in the liver.
Indirect markers indicate alterations in hepatic function, increase in portal hypertension with subsequent splenic enlargement, and/or grade of hepatic inflammation that may correlate with fibrosis stage.
Direct and indirect markers may be used alone or, more commonly, in combination (“composite scores”). The calculation of such scores can be simple (e.g., APRI, FIB-4, FORNS) or based on complicated formulas (e.g., Fibrotest, Fibromax, Fibrosure).
Advantages of surrogate markers are (EASL 2015):
Disadvantages of surrogate markers include (EASL 2015):
|Index||Variables||Formula for calculation||Interpretation|
|Direct surrogate marker|
|MP3||PIIINP, MMP-1||0.5901 (logPIINP[ng/mL]) − 0.1749 (logMMP-1[ng/mL])||<0.3 ≈ F0–2 >0.4 ≈ F3–4 <0.3 ≈ F0–1 >0.4 ≈ F2–4|
|Indirect surrogate markers|
|Forns||Age, plt, γGT, cholesterol||7.811 – 3.131 × ln(plt) + 0.781 × ln(γGT) + 3.467 × ln(age) − 0.014 (cholesterol)||>6.9 ≈ Scheuer 2–4 <4.2 ≈ Scheuer 0–1|
|APRI||AST, plt||([AST/ULN]/plt [× 109/L]) × 100||>1.5 ≈ Ishak 3–6 ≤0.5 ≈ Ishak 0–2|
|Fibroindex||Plt, AST, γGT,||1.738 − 0.064 (plt [× 104/mm3]) + 0.005 (AST [IU/L]) + 0.463 × (γGT[g/dL])||≤1.25 ≈ F0–F1 ≥2.25 ≈ F2–F3|
|Testa||Plt, spleen diameter||Plt count/spleen diameter||>1750 ≈ Ishak ≤2 ≤1750 ≈ Ishak >2|
|Fibrosis probability index||AST, cholesterol, past alcohol intake, HOMA, age||Ex/1 + ex, wherex = −10.929 + (1.827 × ln[AST]) + (0.081 × age) + (0.768 × [past alcohol use graded as 0–2]) + (0.385 × HOMA)||<0.2 ≈ F0–F1 ≥0.8 ≈ F2–F4|
|FIB-4||Plt, AST, ALT, age||(Ages × AST)/(plt count ×||<1.45 ≈ Ishak <4–6 >3.25 ≈ Ishak ≥4–6|
|Bonancini||ALT, AST, INR, plt||Sum (range 0–11) of (plt score) + (ALT/AST score) + (INR score) plt (× 109/L): >340 = 0; 280–339 = 1; 220–279 = 2; 160–219 = 3; 100–159 = 4; 40–99 = 5; <40 = 6 ALT/AST ratio: >1.7 = 0; 1.2–1.7 = 1; 0.6–1.19 = 2; <0.6 = 3 INR: \1.4 = 2||>8 ≈ Knodell 3–4|
|Pohl||AST, ALT, plt||Positive if: AST/ALT ≥1 and platelet count <150 × 109/L||Positive ≈ F3–F4|
|Age-Platelet||Plt, age||Age score + plt score (0–10 possible score) age: <30 = 0; 30–39 = 1; 40–49 = 2; 50–59 = 3; 60–69 = 4; ≥70 = 5. Plt (× 109/L): ≥225 = 0; 200–224 = 1; 175–199 = 2; 150–174 = 3; 125–149 = 4; ≥125 = 5||≥6 ≈ F2–F4|
|Combined direct and indirect surrogate markers|
|SHASTA||HA, AST, albumin||−3.84 + 1.70 (1 if HA 41–85 ng/mL, 0 otherwise) + 3.28 (1 if HA >85 ng/mL, 0 otherwise) + 1.58 (1 if HA <3.5 g/dL, 0 otherwise) + 1.78 (1 if AST >60 IU/L, 0 otherwise)||>0.8 ≈ Ishak ≥3 <0.3 ≈ Ishak ≤2|
|FM||plt, PI, AST, HA, α2-MC, gender, age||−0.007 plt (G/L) − 0.049 PI (%) + 0.012 AST (IU/L) + 0.005 α2-MC (mg/dL) + 0.021 HA (μg/L) − 0.270 urea (mmol/L) + 0.027 age (years) + 3.718||≥F2|
|Hepascore||HA, α2-MC, γGT, age, gender||y/1 + y, where y = exp [−4.185818 − (0.0249 × age) + (0.7464 × sex) + (1.0039 × α2-MC) + (0.0302 × HA) + (0.0691 × bilirubin) − (0.0012 × γGT)]||≥0.5 ≈ F2–F4 <0.5 ≈ F0–F1|
Primary endpoints of the studies that evaluated surrogate markers vary from discrimination of no fibrosis and cirrhosis to the determination of the stages of fibrosis. With the occurrence of the new antiviral treatment options for HCV patients that allow the treatment even in decompensated patients with advanced cirrhosis, the detection of fibrosis in HCV patients has become a less relevant clinical information. However, in areas with limited treatment access where treatment is prioritised the determination of advanced fibrosis stages may guide the decision of whom to treat first. In addition patients with liver cirrhosis need continuous monitoring even after viral elimination due to an increased risk of the occurrence of hepatocellular carcinoma.
From the whole range of surrogate markers only a few are in broad clinical use. The simple APRI score has been widely studied in HBV and HCV as well as in co-infected patients (Cacoub 2008, Lebensztejn 2005, Vallet-Pichard 2008, Wai 2006). A comprehensive meta-analysis of the performance of the APRI test showed that its major strength is the exclusion of significant fibrosis, defined as F2-F4, or cirrhosis with cut-offs of 0.5 and 1.5, respectively. Importantly, the test performance varied with the quantity of advanced fibrosis in the different patient groups (Shaheen 2007 & 2008). Fibrotest has also achieved some clinical significance. However, this test may not be available for all patients. Meta-analyses of the predictive performance of Fibrotest summarise that the reliability for the detection of advanced fibrosis or cirrhosis is adequate for clinical practice, and a cut-off of 0.6 has been suggested (Poynard 2007, Shaheen 2007 & 2008). Of note, the reliability for the detection of earlier fibrosis stages appears to be relatively low (Poynard 2007, Shaheen 2008).
It has to be pointed out that the performance of these markers differs among liver diseases. For instance, a study evaluating indirect markers in >2,000 patients with chronic liver diseases detected a higher accuracy for detecting significant fibrosis in HCV patients than in NALFD (Sebastian 2011). A comprehensive paper reviewing the diagnostic accuracy of surrogate markers of fibrosis in HCV patients from 172 studies concluded that these tests based on different biomarkers are equally effective in diagnosing cirrhosis (Chou 2013). Combinations of different scores may be more effective in avoiding biopsies.
Non-invasive markers have potential value beyond the prediction of fibrosis. Surrogate markers and in particular elastography techniques have been evaluated for the prediction of liver-related complications and mortality. A number of studies aimed to test composite scores in this context for a variety of liver diseases such as PBC, alcoholic liver disease or HCV as well as mixed cohorts, describing AUROCs of 0.73 - 0.86 for mortality prediction (Mayo 2008, Naveau 2009, Parkes 2010, Vergniol 2011).
In summary, surrogate markers may support the clinical decision making process, but a single surrogate marker or score cannot replace liver biopsy. On the other hand, attempts have been made to combine different surrogate markers and biopsy in clinical decision algorithms that aim to reduce the need for liver biopsy.
Several methods for ultrasound-based elastography of the liver have been developed. These methods can be subdivided into two categories. The readouts of these measurements are either kPa or m/s, or both. Transient elastography has been available and evaluated since 2005, whereas the other technologies have become commercially available thereafter. Hence, transient elastography is the most common elastography method today but the success in non-invasive evaluation of liver fibrosis obviously has stimulated others manufacturers of ultrasound machines to promote their own specific technology. However, although similar in read-outs, not all specific machines have been evaluated in detail.
1. Shear wave speed techniques and readout values
2. Strain/displacement techniques
Initially elastography was used to assess liver fibrosis stages without the need for biopsy and to exclude cirrhosis. Over time clinicians and researchers broadened the application and tried to answer more questions using elastography:
Transient elastography (TE) is a non-invasive technique to assess liver fibrosis (Sandrin 1999). TE allows the assessment of liver fibrosis by calculating the velocity of a low-frequency transient shear wave produced by a mechanical probe that is placed directly on the skin of the patient. The velocity of the wave that penetrates the liver tissue depends on the stiffness of the liver, which in turn correlates with the extent of liver fibrosis. In practice, a probe is placed in an intercostal space at a position that is comparable to the position for standard liver biopsy. Ten successful measurements are usually necessary for the assessment of liver stiffness. This can be done in less than 5 minutes. At present TE machines are exclusively available from Echosens (FibroScan®). Liver stiffness is expressed in kilo Pascal (kPa). The method is easy to learn and quick, results are available immediately, and a technical assistant can perform the procedure. In most studies, TE displays robust intra- and inter-observer variability (Fraquelli 2007) and may be used in children as well as adults (de Ledinghen 2007).
Normal liver stiffness
Evaluation of liver stiffness in subjects without apparent liver disease shows that liver stiffness is influenced by sex and body mass index (BMI). In general, liver stiffness is higher in men than in women (5.8±1.5 vs. 5.2±1.6 kPa) and in obese vs. non-obese (6.5±1.6 vs. 5.3±1.5 kPa). (Roulot 2008). Interestingly, TE may be used as a screening tool for the general population to identify patients with unrecognised liver disease (Ginès 2016, Roulot 2011).
Taken together one might say that liver stiffness values < 7.5 kPa appear to reflect the normal range, i.e. the absence of advanced liver fibrosis (Castera 2008, Ferraioli 2015).
Common sources of false interpretation of results (usually elevated liver stiffness measurements) have been identified and should be taken into account when setting up TE measurements in clinical routine (Table 3). Acute liver injury such as acute viral or alcoholic hepatitis, or chronic viral hepatitis flares can lead to overestimation of liver fibrosis (Arena 2008, Coco 2007, Sagir 2008). Other interfering conditions include cardiac failure, Valsalva manoeuvre, pulmonary hypertension, amyloidosis, pregnancy, cholestasis, or steatosis, with the latter being more relevant in HCV than in HBV (Arena 2008, Fraquelli 2007). Another relevant artefact is the examination of a patient within 2 hours after a meal, which increases resistance by up to 2 kPa (Mederacke 2009). However, this effect was not observed using CAP for the detection of steatosis (Silva 2019). Special probes have been developed to overcome problems with measurements in children and in obese patients (“S-probe”, “XL-probe”) (Engelmann 2011).
|Obesity (BMI >30 kg/m2)||Use XL probe||Cut-offs may be slightly lower with XL probe|
|Age >52 years|
|Steatosis||Relevant only in HCV patients|
|Non-fasting||Re-measure after 3–6 h fasting period|
|Cardiac failure||Reassessment after cardiac recompensation|
|High necroinflammatory activity (AST/ALT ratio)||Reassessment after cessation of inflammatory flare|
|Ascites||Use other non-invasive procedures such as ARFI, SSI or MR elastography, or re-measure after complete paracentesis|
|Cholestasis||Decompression||Stiffness reduction in PSC is incomplete after stenting, but changes in stiffness during long-term follow-up are associated with severity of fibrosis and outcomes|
Common quality criteria applied to certify an acceptable quality of TE measurements are: 10 successful measurements with >60% successful measurements and an interquartile range (IQR)/median (M) ratio <0.30. However, the relevance of these criteria has been questioned, and a three-category classification system of reliability has been suggested: “very reliable” (IQR/M ≤0.10), “reliable” (0.10 < IQR/M ≤ 0.30, or IQR/M >0.30 with median liver stiffness <7.1 kPa), and “poorly reliable” (IQR/M >0.30 with median liver stiffness ≥7.1 kPa). Applying these categories to the clinical endpoint “cirrhosis” leads to the correct classification of 90.4%, 85.8% and 69.5% patients, respectively (Boursier 2012). In a large overview of 12,000 examinations 4% of measurements with the M-probe were not successful, and 17% were rated as unreliable (Castera 2010). Multivariate assessment of factors responsible for failure or unreliability were obesity and limited operator experience. Interestingly, not BMI in general but a lipohypertrophy in the thoracic belt in particular was the limiting factor for the success rate. It is important to note that the applicability of TE is limited to relatively lean patients (BMI <28 kg/m2), patients without ascites, and “cooperative” patients. The special "XL-probe" for obese patients has broadened the applicability of TE and is recommended for patients with a skin-capsule distance of >2.5 cm (but below 3.5 cm) (Myers 2011). Sequential use of M- and XL-probes show that XL-probes tend to produce higher stiffness measurement values in the same patient as compared to the M-probe, thus the former probes may overestimate liver stiffness in these patients.
Unlike liver histology, no published data is available on the variability (“sampling error”) of TE results. TE correlates well with other surrogate markers of liver fibrosis such as APRI and FIB-4 (Vidovic 2010). In patients with chronic liver disease eligible for TE, liver stiffness values correlate with the stage of fibrosis, irrespective of the underlying disease aetiology. TE has been evaluated in patients with chronic viral hepatitis, PBC, PSC, NASH, haemochromatosis, and Wilson disease. Due to high acceptance by patients, it can easily be used to monitor progression or regression of fibrosis in patients under observation or on therapy (Wilson 2006, Wong 2011). TE has been evaluated for the detection of liver fibrosis in patients with acute and chronic viral hepatitis and has also been positively evaluated for HCV/HIV-coinfected patients and in patients with HCV recurrence posttransplantation (Carrion 2006, de Ledinghen 2006, Maida 2007).
Cut-offs for liver fibrosis
Studies comparing TE with liver biopsy demonstrate both high sensitivity and specificity for the detection of advanced fibrosis and cirrhosis. However, TE performance is less reliable for the detection of fibrosis stages ≥F2 as compared to more advanced stages of liver fibrosis (sensitivity 56-67%), resulting in moderate negative predictive values. Thus, the assessment of liver fibrosis by TE alone may result in the underestimation of liver fibrosis in some patients. Vice versa, if TE predicts significant fibrosis, a biopsy will not be necessary.
An authoritative meta-analysis that evaluated the predictive performance of TE in patients with chronic liver disease suggested that the optimal cut-off value for the diagnosis of significant fibrosis is 7.65 kPa and 13.0 kPa for cirrhosis (Friedrich-Rust 2008). For chronic liver diseases other than HCV the specific cut-off values for cirrhosis are 11.7 kPa in HBV, 10.3 kPa in non-alcoholic fatty liver disease, 17.9 kPa in biliary liver diseases, and 22.7 kPa in alcoholic liver disease if drinking and 12.5 kPa if abstinent (Trapper 2015).
A meta-analysis of the performance of TE in patients with alcoholic liver disease is less enthusiastic about the exactness of TE in this context and suggests to use both TE and liver biopsy sequentially in some cases to establish the correct fibrosis stage in all patients; the authors stress the importance of TE in ruling out cirrhosis or advanced fibrosis rather than defining exact fibrosis stages (Pavlov 2015).
Apparently different diseases have somewhat different cut-offs. However, rather than using fixed cut-offs the application of TE in a more continuous manner and follow-up procedure to assess changes in liver stiffness (Castera 2008). Whereas liver stiffness values >12.5 kPa are highly suggestive for advanced liver fibrosis or cirrhosis, patients with lower values (<7.5 kPa) are unlikely to suffer from advanced disease. Intermediate patients may qualify for liver puncture to clarify fibrosis stage if not answered by other non-invasive procedures.
Since the amount of data for TE and different liver disease etiology is continuously rising, we summarize available cut-offs and potential diagnostic consequences for clinicians in Table 4.
|Disease||Cut-off||Diagnosis||Consequence / comment||References|
|Chronic hepatitis C virus infection||6.8 - 7.6 kPa||Risk of F2 - F4||Antiviral therapy
|13.1 kPa||F4||Check for portal hypertension HCC screening||Friedrich-Rust 2008|
|HIV/HCV co-infection||≥ 7.1 kPa
≥ 12.5 kPa
|TE outperforms APRI and FT||Castera 2014|
|Chronic hepatitis B virus infection||6.6 - 8.8 kPa
> 11.7 kPa
|Chronic hepatitis D virus infection||> 14.0 kPa||Cirrhosis||HDV-infected patients tend to have higher TE values due to higher necroinflammatory activity||Da 2019|
|Non-alcoholic fatty liver disease||< 7.9 kPa
≥ 9.3 kPa
|Rules out F3 fibrosis with 90% sensitivity and specificity
High risk of F3 fibrosis with 90% sensitivity and specificity
|M-probe with significantly lower cut-offs than XL-probe||Wong 2010|
|14.3 kPa (M-probe)
16.8 kPa (XL-probe)
|F4||Screen for complications||Oeda 2019|
|In subjects with F0-F2 fibrosis, the rates of false-positive LSM results for F3-F4 fibrosis increased according to CAP tertiles (7.2% in lower versus 16.6% in middle versus 18.1% in higher)||Petta 2017|
|Alcohol-related liver disease||7.0 kPa
|12.1 kPa in patients with AST < 38 IU/L and bilirubin < 9 µmol/L
25.9 kPa in patients with AST > 75 IU/L and biliurbin > 16 µmol/l
|Primary biliary cholangitis||7.1 kPa
|Cut-off of 2.1 kPa per year was associated with an 8.4-fold increased risk of liver decompensation, liver transplantation, or death||Corpechot 2012|
|<20 kPa and platelets >150,000/mm||No need for screening for esophageal varices||Moctezuma-Velazque 2019|
|Primary sclerosing cholangitis||7.4 kPa
|Progression rate > 1.3 kPa per year is associated with decreased survival||Corpechot 2014|
|Autoimmune hepatitis||5.8 kPa
|Treatment response and fibrosis regression may be monitored by TE||Hartl 2016|
|Haemochromatosis||<6.4 kPa||Rules out significant fibrosis||Limited prospective data||Legros 2015|
|Wilson disease||≥ 9.9 - 10.1 kPa||Cirrhosis||Adult population||Paternostro 2020
|Liver stiffness is higher at diagnosis and decreases with treatment||Stefanescu 2016|
|Cystic fibrosis (CF)-associated liver disesae||≥ 5.2 - 5.95 kPa||Suspicion of CF-associated liver diseases||Combination with APRI may yield higher diagnostic value||Lam 2019|
|≥ F2 in general population
≥ F2 in patients at risk for alcohol-related liver disease
|Screening with TE is cost-effective||Serra-Buriell 2019|
|Portal hypertension||> 25 kPa||High risk for varices||Endoscopy screening for varices||Castera 2011
|HCC||> 25 kPa||> 45-fold increase for risk of developing HCC in viral hepatitis, but increased risk starts at 10.0 kPa||HCC screening||Masuzaki 2009
Elastography may be used for monitoring stiffness changes over time. Rather than focusing at a given stiffness at a certain time point clinicians may use stiffness measurements for monitoring changes in liver stiffness. Studies highlighted that the consecutive increase of liver stiffness is related with higher mortality and liver-related events such as variceal bleeding or hepatic encephalopathy, especially in patients with liver stiffness >12.5 kPa (Perrez-Latorre 2016, Vergiol 2014).
TE may be used to monitor changes in liver stiffness following either the natural course or changes in stiffness on and after treatment. Whereas in the first scenario prediction of disease progression rates may be useful, the latter reflects the regression of inflammation and/or fibrosis. The longitudinal monitoring of patients with chronic HBV and HCV infections but also Wilson disease has documented reduction in liver stiffness upon treatment response (Andersen 2011, Fung 2011, Hezode 2011).
In addition to the assessment of liver fibrosis stages, TE might be used to predict the presence of portal hypertension (Rockey 2008). Of note, a cut-off value of >25 kPa has been associated with a >45-fold increased risk of developing HCC in viral hepatitis. However, the risk seems to increase in a linear fashion starting from 10 kPa (Fung 2011, Masuzaki 2009). Furthermore, TE values >21 kPa are associated with portal hypertension as well as the risk of portal hypertension-related complications and indicate that endoscopy is indicated to assess oesophageal varices as well as the need for primary prophylaxis with non-selective β-blockers (Castera 2011, Robic 2011).
A combination of non-invasive tests in the form of surrogate markers, elastography methods or both have the potential of reducing the number of biopsies, lead priorisation strategies for treatment and surveillance and predict morbidity and mortality. Despite a number of studies in this field we currently do not have a definite algorithm that is widely accepted in clinical practice. However, the WHO highlights the combination of APRI, FIB-4 and TE in order to identify patients at risk and to start treatment in HCV-infected patients (WHO 2014).
The current EASL guidelines for the use of non-invasive assessment of liver fibrosis suggest a number of distinct algorithms for different liver disease. The proposed algorithm for HCV patients is shown in Figure 1. The basic principle is that TE is combined with a serum marker test for liver fibrosis. Concordant results may reduce the need for biopsy while inconclusive results may be a reason for biopsy. The experience of the authors of this chapter is however that for the sake of determining the stage of liver fibrosis it is hardly ever necessary to perform biopsy unless other information is needed (e.g., evidence for autoimmune hepatitis); furthermore, patients are reluctant to undergo biopsy due to the widespread information on non-invasive alternatives.
Besides TE as the primary tool, shear wave technology to assess liver fibrosis, ARFI and SSI have now been more intensively studied for the assessment of fibrosis, cirrhosis and complications. ARFI and SSI both use a region of interest that can be adapted by the investigator. ARFI is implemented in Philips and Siemens ultrasound machines. Ideally, the region of interest (10×5 mm) is set 1-2 cm below the liver capsule. As in TE, ten sequential measurements are performed and the interquartile range is used to assess the accuracy of fibrosis evaluation. Although ARFI and SSI can be used in obese patients and patients with ascites, there is a subgroup of patients in whom reliable results may not be obtained (Cassinotto 2014), comprising up to 3% in ARFI cohorts and up to 11% in SSI studies (Cassinotto 2014). A recent meta-analysis reported that the accuracy for the prediction of fibrosis stages ≥F2, ≥F3 and cirrhosis were 0.87, 0.91 and 0.93, respectively (Friedrich-Rust 2012). A recently published head-to-head analysis comparing TE with ARFI showed comparable results for both methods (Colombo 2012). However, ARFI was less prone to methodological failure than TE. Both methods seem reliable for the detection of advanced fibrosis (Colombo 2012, Rizzo 2011, Sporea 2012). As with TE, many procedure- and patient-related factors may influence test results, in particular increased stiffness during hepatitis flares (Chen 2012, Karlas 2011).
Another shear wave-based technology has recently been introduced for the diagnosis of liver fibrosis (real-time SSI by Supersonic Imaging), combining TE stiffness calculations with the possibility of defining regions of interest as in ARFI. While this method has not yet been widely used, early studies show a comparable diagnostic accuracy compared to TE (Ferraioli 2012a, Ferraioli 2012b). The comparison of all three methods (ARFI, TE, SSI) with liver biopsy in patients with fatty liver disease did not reveal substantial differences although SSI may be more reliable in the diagnosis of >F4 fibrosis in these cases but no differences between SSI and TE or ARFI and TE have been reported in this context. Interestingly in this patient cohort the cut-offs were very close for SSI and TE and substantially lower than for patients with chronic viral hepatitis (6.3/6.2 kPa for ≥F2, 8.3/8.2 kPa for ≥F3, and 10.5/9.5 kPa for F4, respectively) (Cassinotto 2015). In principle these results were confirmed in unselected cases of patients with chronic liver disease (Gerber 2015).
Concerning data on correlation with histological fibrosis stages, TE, ARFI and SSI all suffer from the same limitations with overlapping ranges of stiffness results for individual fibrosis stages. However, they all seem adequate in detecting the presence of fibrosis and cirrhosis. Numerous comparisons have been made in order to detect an advantage of one machine over another. In the end none of these studies identified substantial differences for choosing one method over the other. A detailed critical review on available ultrasound methods with all pros and cons of each single methods has been published recently and is recommended for further reading (Ferriaioli 2015).
Computational methods may improve the specifity and sensitivity for the diagnosis of liver fibrosis stages. For 2D-Shear wave elastography a neuronal network was applied and predictions were compared to histology stages. This approach may maximise sensitivity and specificity (Wang 2018), but predictions for lower fibrosis stages were not as markedly improved as for advanced fibrosis. These techniques highlight the potential of smart computer algorithms ("artificial intelligence") to support non-invasive assessment of liver phenotypes.
A number of different imaging techniques such as conventional ultrasound, real-time elastography, portal venous transit time, MR imaging have been used for the assessment of liver fibrosis. None of these methods has yet achieved an overall clinical acceptance regarding the assessment of liver fibrosis, either due to low sensitivity and/or specificity, or high costs.
Non-invasive markers for the staging of liver fibrosis are at the edge of replacing liver histology as the gold standard, at least in hepatitis C. This is due to the fact that outcome studies with clear endpoints like mortality are available (Vergniol 2011, Pakres 2010, Naveau 2009, Mayo 2008) or under investigation (NCT01241227, NCT02037867 and others). The advantages of these non-invasive tests in comparison to liver biopsy are striking. In order to overcome test limitations and to benefit from their specific advantages, a frequent strategy is to combine different non-invasive tests, using liver biopsy only in case of doubt. However, algorithms vary greatly in performance and acceptance. Whereas some authors have estimated a reduction in liver biopsies of 30%, others have estimated reductions of up to 80% (Leroy 2007, Sebastiani 2004, Sebastiani 2006, Sebastiani 2007). New strategies with sophisticated algorithms may overcome these limitations and a combination of TE with FibroMeter give results that may be detailed and reliable on liver fibrosis stage without any need for histology. However, only one study from France has described this method, which needs to be cross-validated by independent groups (Boursier 2011a, Boursier 2011b).
Patients not being in regular care are diagnosed in late stages when liver decompensation or liver cancer develops. The diagnosis is rarely made in early stages-when liver fibrosis is mild to moderate but cirrhosis is not yet established-because the disease is asymptomatic. Liver biopsy is not a suitable procedure for population-based screening for fibrosis and/or fatty liver but non-invasive methods might be. A comprehensive survey on the frequency of liver fibrosis in population-based studies revealed progressive disease in up to 25.7% of participants (Harris 2017). In a population-based screening study using transient elastography, prevalence estimates of increased liver stiffnesss (≥ 6.8, ≥ 8.0, and 9.0 kPa) were 9.0%, 5.8%, and 3.6%, respectively. Elastography was more accurate than alanine aminotransferase, NAFLD fibrosis score, or FIB-4 (Caballería 2018). The minimum acceptable accuracy of non-invasive tests to diagnose cirrhosis with equivalence to liver biopsy depends on cirrhosis mortality and prevalence (Majumdar 2019): At 5% and 20% cirrhosis prevalence, sensitivities and specificities are 89% and 88%, and 94% and 85%, respectively (if the physician found it acceptable to subject 20 patients to biopsy to find one correct case with cirrhosis). Using these criteria, TE alone and TE plus FibroTest are the only existing tests that were better than or equal to biopsy at diagnosing cirrhosis at 5% prevalence (Majumdar 2019). In a recent cost-effectiveness guided approach it could be demonstrated that a 9.1 kPa TE cut-off provided the best accuracy for the diagnosis of significant fibrosis (≥ F2) in general population settings, whereas a threshold of 9.5 kPa was optimal for populations at-risk of alcohol-related liver disease. TE with the proposed cut-offs outperformed fibrosis scores in terms of accuracy. Screening with TE was cost-effective with mean incremental cost-effectiveness ratios ranging from 2,570 €/QALY (95% CI 2,456-2,683) for a population at-risk of alcohol-related liver disease (age ≥45 years) to 6,217 €/QALY (95% CI 5,832-6,601) in the general population. Overall, there was a 12% chance of TE screening being cost saving across countries and populations (Serra-Burriel 2019).
Nowadays virus-induced chronic liver diseases can be effectively treated by well tolerated antiviral drug regimens, but the epidemic of non-alcoholic fatty liver disease (NAFLD) demonstrates an exponential increase in burden of disease. The mechanisms contributing to hepatic steatosis and the development of an inflammatory state with progression to liver disease are under intense investigation. Patients with NAFLD, in particular with non-alcoholic steatohepatitis (NASH), suffer from an increased risk of advancing to progressive liver disease with fibrosis, eventually resulting in cirrhosis and the need for liver transplantation.
The challenges for the development non-invasive diagnostic strategies are:
As for liver fibrosis serological markers either as single markers or combined in scores are being evaluated in comparison to liver histopathology. It is debated whether non-invasive tests are comprehensive for the detection and classification of disease severity of NAFLD (Bedossa 2018; Castera 2018). It can be expected that non-invasive techniques will play a more important role in the diagnostic work-up of patients with fatty liver disease.
Serological markers of steatosis in NAFLD are also being evaluated. Similarly to the history of non-invasive fibrosis assessment, attempts are made to established steatosis-specific markers and scores that aim to diagnose steatosis by the combination of different parameters with more or less specificity for steatosis and inflammation in fatty liver disease.
Studies also aim to distinguish the necoinflammatory state, i.e. NASH, from simple steatosis. A comprehensive review on this topic has been published by Vilar-Gomez and Chalasani (Vilar-Gomez 2018). Examples of specific markers for NAFLD/NASH are cytokeratin 18 and fibroblast growth factor 21, which are released into the circulation in response to oxidative stress, hepatocyte apoptosis and inflammation. However, a recent meta-analysis came to the conclusion that current non-invasive tests do not accurately differentiate NASH from simple steatosis (Verhaegh 2018).Further efforts are needed to identify more sensitive and specific markers and scores.
As for liver fibrosis, several studies aim to increase the diagnostic accuracy by combining different tests in NAFLD. In the case of NAFLD-associated fibrosis, the sequential use of liver stiffness measurement, NFS and FIB-4 has led to an improvement of correct classification. However, the best combination and sequence of makers is yet to be defined (Petta 2017). In the current German guideline, two scores that combine a number of factors have been included (Table 5). The guideline has also suggested an algorithm for the diagnostic work up of NAFLD (which needs more evaluation). It concludes that non-invasive steatosis assessment may be done by applying the FLI or MRI criteria. For the assessment of advanced fibrosis in NAFLD, the NFS score is applicable.
Whereas the detection of liver fibrosis via TE is hampered by multiple factors, this may also be the case for serum markers of NAFLD. For instance, it could be shown that the NAFLD fibrosis score (and the FIB-4 score) is inaccurate, especially in patients aged 65+ (McPherson 2017). This may explain the results of a recent meta-analysis (Verhaegh 2018) that showed that the majority of non-invasive markers have no sufficient diagnostic value to reliably discriminate steatosis and NASH. As in liver fibrosis authors aim to further increase the diagnostic accuracy by combining different tests in fatty liver disease. In the case of liver fibrosis in NAFLD, the sequential use of liver stiffness measurement, NFS and FIB-4 lead to better classification. However, the best combination and sequence of markers is yet to be defined (Petta 2017).
|Index||Variables||Formula for calculation||Interpretation|
|Fatty liver Index (FLI)||BMI, γGT, triglycerides, waist circumference||(e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (GGT) + 0.053*waist circumference - 15.745) / (1 + e 0.953*loge (triglycerides) + 0.139*BMI + 0.718*loge (ggt) + 0.053*waist circumference - 15.745) * 100||Cut off <30: Likelihood-ratio (LR) of 0.2 with a sensitivity of 82% that no steatosis is present
Cut off had specificity of 86 % and positive LR of 4.3 that steatosis is present
|NAFLD fibrosis score (NFS)||Age, BMI, diabetes, AST, ALT, plt, albumin||−1.675 + 0.037 × age (years) + 0.094 × BMI (kg/m2) + 1.13 × IFG/diabetes (yes = 1, no = 0) + 0.99 × AST/ALT ratio − 0.013 × platelets (×109/l) − 0.66 × albumin (g/dL).||Cut off < -1.455: Absence of significant fibrosis (93% certainty)
Cut off > 0.676
Presence of significant fibrosis (90% certainty)
Can elastography reliably assess fibrosis in these patients and what are the precautions we need to consider?
Up to date there is no conclusive evidence that increased liver stiffness is a good predictor for the presence and severity of lipid storage in the liver in patients suspected of NAFLD. In addition, TE and other shear wave elastography methods can reliably predict cirrhosis (F4: sensitivity 92%, specificity 92%), but the detection of early fibrosis stages appears to be limited (Kwok 2014). Finally, elastography is not a reliable tool to detect necroinflammatory changes in the liver.
Liver fat content has been historically assessed by ultrasound using a semi-quantitative estimate or by liver histology. Steatosis is a growing problem whether in the context of non-alcoholic steatohepatitis or as a co-factor in the metabolic syndrome and other liver diseases. Until recently reliable quantitative measures of the degree of steatosis were missing. A novel tool to overcome this diagnostic gap may be CAP. This analysis is available in TE machines from Echosens that measure the attenuation of the intensity of the echo from the ultrasound signal in the liver (available for the M-probe and the XL-probe). It is calculated only for reliable TE measurements and does not lengthen the TE procedure. The measurement is expressed in dB/m. Korean investigators defined a normal upper range of 266 dB/m in potential liver donors, all with histology proven fat contents <5%. However, in a less strictly selected patient population defined as a “health check-up” cohort, a higher upper limit of normal of 288 dB/m was defined, which may be due to the inclusion of patients with diabetes (Chon 2014). A recent study defined histopathological categories of liver steatosis (S) grades (S0: ≤10%, S1: 11 – 33%, S2: 34 – 66%, S3: ≥67%) and correlated these with CAP results. Using receiver operating statistics, the authors defined cut-offs with a sensitivity >90% for all grades of steatosis (215 dB/m for S ≥1, 252 dB/m for S ≥2, 296 dB/m for S3) (de Ledinghen 2012). In patients with chronic hepatitis C, corresponding cut-off values of 222 dB/m, 233 dB/m and 290 dB/m were identified for discriminating the steatosis grades (Sasso 2012).
As with TE, CAP results are also influenced by multiple factors and vary with the cause of the disease (de Ledinghen 2014). A recent meta-analysis focused on the confounders of high CAP values and found that besides NAFLD, diabetes and BMI are independently influencing CAP values. The authors also point out that the influence of these confounders may change according to the prevalence of steatosis in the studied population. According to their results in 2,735 patients, they determined the following cut-offs for >S0, >S1 and >S2: 248, 268, and 280 dB/m, respectively (Karlas 2017). In contrast to TE, CAP measurements seem not to be influenced by recent meals.
Non-invasive tests have still not completely replaced liver biopsies, but smart combinations of non-invasive tools avoid this more invasive procedure in many patients. Whatever the current standard of care, the patient should be informed about the non-invasive tests, their applicability, and their limitations. The decision to perform a liver biopsy should ultimately be made together with the informed patient.
Andersen ES, Moessner BK, Christensen PB, et al. Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. European journal of gastroenterology & hepatology 2011;23:41-44.
Andersen ES, Weiland O, Leutscher P, et al. Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scandinavian journal of gastroenterology 2011;46:760-766.
Arena U, Vizzutti F, Abraldes J, et al. Reliability of transient elastography for the diagnosis of advanced fibrosis in chronic hepatitis C. Gut 2008.
Arena U, Vizzutti F, Corti G, et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008;47:380-384.
Batts KP, Ludwig J. Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol 1995;19:1409-1417.
Bedossa P. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. Liver int 2018. Epub ahead of print.
Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003;38:1449-1457.
Boursier J, de Ledinghen V, Zarski JP, et al. A new combination of blood test and fibroscan for accurate non-invasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011;106:1255-1263.
Boursier J, Zarski JP, de Ledinghen V, et al. Determination of reliability criteria of liver stiffness evaluation by transient elastography. Hepatology 2012;55:58-67.
Caballería L, Pera G, Arteaga I, et al. High prevalence of liver fibrosis among European adults with unknown liver disease: a population-based study. Clin Gastroenterol Hepatol 2018 [Epub ahead of print]
Cacoub P, Carrat F, Bedossa P, et al. Comparison of non-invasive liver fibrosis biomarkers in HCV/HIV co-infected patients: The fibrovic study – ANRS HC02. J Hepatol 2008;48:765-773.
Calvaruso V, Burroughs AK, Standish R, et al. Computer-assisted image analysis of liver collagen: relationship to Ishak scoring and hepatic venous pressure gradient. Hepatology 2009;49:1236-1244.
Calvaruso V, Dhillon AP, Tsochatzis E, et al. Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation. Journal of gastroenterology and hepatology 2012;27:1227-1232.
Carrion JA, Navasa M, Bosch J, Bruguera M, Gilabert R, Forns X. Transient elastography for diagnosis of advanced fibrosis and portal hypertension in patients with hepatitis C recurrence after liver transplantation. Liver Transpl 2006;12:1791-1798.
Cassinotto C, Lapuyade B, Mouries A, et al. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan®. J Hepatol. 2014;61:550-7.
Cassinotto C, Boursier J, De Ledinghen V et al. Liver stiffness in nonalcoholic fatty liver disease: A comparison of Supersonic Shear Imaging, FibroScan and ARFI with liver biopsy. Hepatology. 2016;63:1817-27.
Castera L. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Non-invasive tests are enough. Liver Int. Epub ahead of print
Castera L. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005;128:343-350.
Castera L. Forns X, ALberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol. 2008 May;48(5):835-47
Castéra L, Foucher J, Bernard PH et al. Hepatology. 2010 Mar;51(3):828-35
Castera L, Pinzani M, Bosch J. Non Invasive Evaluation of Portal Hypertension Using Transient Elastography. J Hepatol. 2012;56:696-703
Castera L, Winnock M, Pambrun E et al. Comparison of transient elastography (FibroScan), FibroTest, APRI and two algorithms combining these non-invasive tests for liver fibrosis staging in HIV/HCV coinfected patients: ANRS CO13 HEPAVIH and FIBROSTIC collaboration. HIV Med. 2014;15:30-9. Chan HL, Wong GL, Choi PC, et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. Journal of viral hepatitis 2009;16:36-44.
Chen SH, Li YF, Lai HC, et al. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. BMC gastroenterology 2012;12:105.
Cholongitas E, Senzolo M, Standish R, et al. A systematic review of the quality of liver biopsy specimens. Am J Clin Pathol 2006;125:710-721.
Chon YE, Choi EH, Song KJ et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 2012;7:e44930.
Chon YE, Jung KS, Kim KJ, et al. Normal Controlled Attenuation Parameter Values: A Prospective Study of Healthy Subjects Undergoing Health Checkups and Liver Donors in Korea. Dig Dis Sci. 2014;60(1):234-42.
Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Ann Intern Med. 2013;159:372.
Coco B, Oliveri F, Maina AM, et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007;14:360-369.
Colombo S, Buonocore M, Del Poggio A, et al. Head-to-head comparison of transient elastography (TE), real-time tissue elastography (RTE), and acoustic radiation force impulse (ARFI) imaging in the diagnosis of liver fibrosis. Journal of gastroenterology 2012;47:461-469.
Corpechot C, Carrat F, Poujol-Robert A et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology. 2012;56:198-208.
Corpechot C, Gaouar F, El Naggar A et al. Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis. Gastroenterology. 2014;146:970-9.
Da BL, Surana P, Takyar V et al. Vibration-controlled transient elastography for the detection of cirrhosis in chronic hepatitis D infection. J Viral Hepat. 2019 Epub ahead of print.de Ledinghen V, Douvin C, Kettaneh A, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006;41:175-179.
de Ledinghen V, Le Bail B, Rebouissoux L, et al. Liver stiffness measurement in children using FibroScan: feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterol Nutr 2007;45:443-450.
de Ledinghen V, Vergniol J, Foucher J, Merrouche W, le Bail B. Non-invasive diagnosis of liver steatosis using controlled attenuation parameter (CAP) and transient elastography. Liver international : official journal of the International Association for the Study of the Liver 2012;32:911-918.
de Ledinghen V, Vergniol J, Capdepont M et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014;60(5):1026-31.
Degos F, Perez P, Roche B, et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). Journal of hepatology 2010;53:1013-1021.
Denzer U, Arnoldy A, Kanzler S, Galle PR, Dienes HP, Lohse AW. Prospective randomized comparison of minilaparoscopy and percutaneous liver biopsy: diagnosis of cirrhosis and complications. J Clin Gastroenterol 2007;41:103-110.
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
DiMichele DM, Mirani G, Wilfredo Canchis P, Trost DW, Talal AH. Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. Haemophilia 2003;9:613-618.
EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63(1):237-64
Engelmann G, Gebhardt C, Wenning D, et al. Feasibility study and control values of transient elastography in healthy children. Eur J Pediatr 2011.
Ferraioli G, Tinelli C, Dal Bello B, Zicchetti M, Filice G, Filice C. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study. Hepatology 2012;56:2125-2133.
Ferraioli G, Tinelli C, Zicchetti M, et al. Reproducibility of real-time shear wave elastography in the evaluation of liver elasticity. European journal of radiology 2012;81:3102-3106.
Ferraioli G, Filice C, Castera L et al. WFUMB guidelines and recommendations for clinical use of ultrasound elastography: Part 3: liver. Ultrasound Med Biol. 2015;41(5):1161-79
Foucher J, Chanteloup E, Vergniol J, et al. Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006;55:403-408.
Fraquelli M. Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007;56:968.
Fraquelli M, Rigamonti C. Diagnosis of cirrhosis by transient elastography: what is hidden behind misleading results. Hepatology 2007;46:282; author reply 282-283.
Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-172.
Friedman SL, Rockey DC, Bissell DM. Hepatic fibrosis 2006: report of the Third AASLD Single Topic Conference. Hepatology 2007;45:242-249.
Friedrich-Rust M, Nierhoff J, Lupsor M, et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012;19:e212-e219.
Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008;134:960-974.
Fung J, Lai CL, Seto WK, Wong DK, Yuen MF. Prognostic significance of liver stiffness for hepatocellular carcinoma and mortality in HBeAg negative chronic hepatitis B. J Viral Hepat 2011;18:738-744.
Fung J, Lai CL, Wong DK, Seto WK, Hung I, Yuen MF. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. Journal of viral hepatitis 2011;18:e200-205.
Gerber L, Kasper D, Fitting D et al. Assessment of liver fibrosis with 2-D shear wave elastography in comparison to transient elastography and acoustic radiation force impulse imaging in patients with chronic liver disease. Ultrasound Med Biol. 2015. (epub ahead of print)
Ginès P, Graupera I, Lammert F,et al. Screening for liver fibrosis in the general population: a call for action. Lancet Gastroenterol Hepatol 2016;1:256-260
Gronbaek K, Christensen PB, Hamilton-Dutoit S, et al. Interobserver variation in interpretation of serial liver biopsies from patients with chronic hepatitis C. J Viral Hepat 2002;9:443-449.
Hartl J, Denzer U, Ehlken H et al. Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. J Hepatol 2016.;65:769-775.
Harris R, Harman DJ, Card TR et al. Prevalence of clinically significant liver disease within general population, as definded by non-invasive markers of liver fibrosis: a systematic review. Lancet Gastroenterol Hepatol 2017. Epub ahead of Print.
He L, Deng L, Zhang Q, Guo J et al. Diagnostic value of CK-18, FGF-21 and related biomarker panel in non-alcoholic fatty liver disease: a systemativ review and meta-analysis. Biomed Res Int 2017. Epub ahead of print.
Helmreich-Becker I, Schirmacher P, Denzer U, Hensel A, Meyer zum Büschenfelde KH, Lohse AW. Minilaparoscopy in the diagnosis of cirrhosis: superiority in patients with Child-Pugh A and macronodular disease. Endoscopy 2003;35:55-60.
Hezode C, Castera L, Roudot-Thoraval F, et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Alimentary pharmacology & therapeutics 2011;34:656-663.
Hui AY, Liew CT, Go MY, et al. Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. Liver Int 2004;24:611-618.
Isgro G, Calvaruso V, Andreana L, et al. The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. Journal of gastroenterology 2012.
Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995;22:696-699.
Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy – indications, adequacy, quality of specimens, and complications – a systematic review. J Hepatol 2007;47:284-294.
Karlas T, Pfrepper C, Wiegand J, et al. Acoustic radiation force impulse imaging (ARFI) for non-invasive detection of liver fibrosis: examination standards and evaluation of interlobe differences in healthy subjects and chronic liver disease. Scand J Gastroenterol 2011;46:1458-1467.
Karlas T, Petroff D, Sasso M et al. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. 2017;66:1022-1030.
Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
Kwok R, Tse YK, Wong GL et al. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39(3):254-69.
Lam S, Nettel-Aguirre A, Van Biervliet S et al. Transient Elastography in the Evaluation of Cystic Fibrosis-Associated Liver Disease: Systematic Review and Meta-analysis. J Can Assoc Gastroenterol. 2019;2:71-80.
Lebensztejn DM, Skiba E, Sobaniec-Lotowska M, Kaczmarski M. A simple noninvasive index (APRI) predicts advanced liver fibrosis in children with chronic hepatitis B. Hepatology 2005;41:1434-1435.
Legros L, Bardou-Jacquet E, Latournerie M et al. Non-invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis. Liver Int. 2015;35:1731-8.
Leroy V. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007;46:775-782.
Lupsor M, Badea R, Stefanescu H, et al. Analysis of histopathological changes that influence liver stiffness in chronic hepatitis C. Results from a cohort of 324 patients. Journal of gastrointestinal and liver diseases : JGLD 2008;17:155-163.
Maida I, Soriano V, Barreiro P, Rivas P, Labarga P, Nunez M. Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. AIDS Res Hum Retroviruses 2007;23:801-804.
Majumdar A, Campos S, Gurusamy J, et al. Defining the minimum acceptable diagnostic accuracy of noninvasive fibrosis testing in cirrhosis: a decision analytic modeling study. Hepatology 2019;doi: 10.1002/hep.30846.
Mammen T, Keshava SN, Eapen CE, et al. Transjugular liver biopsy: a retrospective analysis of 601 cases. J Vasc Interv Radiol 2008;19:351-358.
Marcellin P, Ziol M, Bedossa P, et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver international : official journal of the International Association for the Study of the Liver 2009;29:242-247.
Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009;49:1954-1961.
Mayo MJ, Parkes J, Adams-Huet B,et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology. 2008;48:1549-57.
McPherson S, Hardy T, Dufour JF et al. Age as a confounding factor for the accurate non-invasive diagnosis of advanced NAFLD fibrosis. Am J Gastroenterol. 2017;112:740-51.
Mederacke I, Wursthorn K, Kirschner J, et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int 2009;29:1500-1506.
Moctezuma-Velazquez C, Saffioti F, Tasayco-Huaman S et al. Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Am J Gastroenterol. 2019;114:446-452.
Moessner BK, Andersen ES, Weis N, et al. Previously unrecognized advanced liver disease unveiled by transient elastography in patients with Haemophilia and chronic hepatitis C. Haemophilia 2011;17:938-943.
Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int 2008;28:705-712.
Myers RP, Pollett A, Kirsch R, et al. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver international : official journal of the International Association for the Study of the Liver 2012;32:902-910.
Myers RP, Pomier-Layrargues G, Kirsch R, et al. Feasibility and diagnostic performance of the fibroscan xl probe for liver stiffness measurement in overweight and obese patients. Hepatology 2011.
Nahon P, Kettaneh A, Tengher-Barna I et al. Assessment of liver fibrosis using transient elastography in patients with alcoholic liver disease. J Hepatol. 2008; 49:1062-8.
Naveau S, Gaudé G, Asnacios A, et al.Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology. 2009;49:97-105.
Nguyen-Khac E, Thiele M, Voican C et al. Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3(9):614-625.
Oeda S, Takahashi H, Imajo K et al. Accuracy of liver stiffness measurement and controlled attenuation parameter using FibroScan® M/XL probes to diagnose liver fibrosis and steatosis in patients with nonalcoholic fatty liver disease: a multicenter prospective study. J Gastroenterol. 2019 [Epub ahead of print].
Ogawa E, Furusyo N, Toyoda K, et al. Transient elastography for patients with chronic hepatitis B and C virus infection: Non-invasive, quantitative assessment of liver fibrosis. Hepatol Res 2007;37:1002-1010.
Oliveri F, Coco B, Ciccorossi P, et al. Liver stiffness in the hepatitis B virus carrier: a non-invasive marker of liver disease influenced by the pattern of transaminases. World journal of gastroenterology : WJG 2008;14:6154-6162.
Paternostro R, Pfeiffenberger J, Ferenci P et al. Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. Liver Int. 2020 [Epub ahead of print]
Parkes J, Roderick P, Harris S, et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut. 201;59:1245-51.
Pavlov CS, Casazza G, Nikolova D et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Database Syst Rev. 2015.
Pérez-Latorre L, Rivero-Juárez A, Hontañón V et al. Prognostic Value of Transient Elastography in Human Immunodeficiency Virus Infected Patients With Chronic Hepatitis C. Open Forum Infect Dis. 2016 Oct 3;3(4):ofw212. eCollection 2016
Petta S, Wong VW, Camma C et al. Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD. Aliment Pharmacol Ther 2017;46:617-27.
Petta S, Wong VW, Camma C et al. Improved noninvasive prediction of liver fibrosis by liver stiffness measurement in patients with non-alcoholic fatty liver disease accounting for controlled attenuation paramenter values. Hepatology 2017;65:1145-55.
Petz D, Klauck S, Rohl FW, Malfertheiner P, Roessner A, Rocken C. Feasibility of histological grading and staging of chronic viral hepatitis using specimens obtained by thin-needle biopsy. Virchows Arch 2003;442:238-244.
Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol 1986;2:165-173.
Pinzani M, Vizzutti F, Arena U, Marra F. Technology Insight: noninvasive assessment of liver fibrosis by biochemical scores and elastography. Nat Clin Pract Gastroenterol Hepatol 2008;5:95-106.
Poynard T, Morra R, Halfon P, et al. Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007;7:40.
Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002;97:2614-2618.
Rizzo L, Calvaruso V, Cacopardo B, et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. The American journal of gastroenterology 2011;106:2112-2120.
Robic MA, Procopet B, Métivier S, et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol. 2011;55:1017-24.
Rockey DC. Noninvasive assessment of liver fibrosis and portal hypertension with transient elastography. Gastroenterology 2008;134:8-14.
Roulot D, Costes JL, Buyck JF, et al. Transient elastography as a screening tool for liver fibrosis and cirrhosis in a community-based population aged over 45 years. Gut 2011;60:977-984.
Roulot D, Czernichow S, Le Clesiau H, Costes JL, Vergnaud AC, Beaugrand M. Liver stiffness values in apparently healthy subjects: Influence of gender and metabolic syndrome. J Hepatol 2008;48:606-613.
Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005;41:257-264.
Sagir A, Erhardt A, Schmitt M, Haussinger D. Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage. Hepatology 2008;47:592-595.
Sandrin L, Catheline S, Tanter M, Hennequin X, Fink M. Time-resolved pulsed elastography with ultrafast ultrasonic imaging. Ultrason Imaging 1999;21:259-272.
Sasso M, Miette V, Sandrin L, Beaugrand M. The controlled attenuation parameter (CAP): a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clinics and research in hepatology and gastroenterology 2012;36:13-20.
Sasso M, Tengher-Barna I, Ziol M, et al. Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan((R)): validation in chronic hepatitis C. Journal of viral hepatitis 2012;19:244-253.
Schirmacher P, Fleig WE, Dienes HP. [Biopsy diagnosis of chronic hepatitis]. Z Gastroenterol 2004;42:175-185.
Schwarz KB, Zellos A, Stamato L, et al. Percutaneous liver biopsy in hemophiliac children with chronic hepatitis C virus infection. J Pediatr Gastroenterol Nutr 2008;46:423-428.
Sebastiani G. Stepwise combination of algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2004;44:686-693.
Sebastiani G, Alberti A. Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006;12:3682-3694.
Sebastiani G, Vario A, Guido M, Alberti A. Sequential algorithms combining non-invasive markers and biopsy for the assessment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2007;13:525-531.
Sebastiani G, Castera L, Halfon P, et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosisbiomarkers: an international study of 2411 cases. Aliment Pharmacol Ther. 2011;34:1202-16.
Serra-Burriel M, Graupera I, Torán P et al. Transient elastography for screening of liver fibrosis: Cost- effectiveness analysis from six prospective cohorts in Europe and Asia. J Hepatol. 2019;71(6):1141-1151.
Shaheen AA, Myers RP. Systematic Review and Meta-Analysis of the Diagnostic Accuracy of Fibrosis Marker Panels in Patients with HIV/Hepatitis C Coinfection. HIV Clin Trials 2008;9:43-51.
Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007;102:2589-2600.
Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003;38:427-432.
Skripenova S, Trainer TD, Krawitt EL, Blaszyk H. Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007;60:321-324.
Sporea I, Bota S, Peck-Radosavljevic M, et al. Acoustic Radiation Force Impulse Elastography for fibrosis evaluation in patients with chronic hepatitis C: An international multicenter study. European journal of radiology 2012;81:4112-4118.
Stefanescu AC, Pop TL, Stefanescu H et al. Transient elastography of the liver in children with Wilson's disease: Preliminary results. J Clin Ultrasound. 2016;44:65-71.
Talwalkar JA, Kurtz DM, Schoenleber SJ, West CP, Montori VM. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic reviewand meta-analysis. Clin Gastroenterol Hepatol. 2007; 5:1214-20.
Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion 2003;67:138-145.
TFMCSG. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994;20:15-20.
Tapper EB, Castera L, Afdhal NH. FibroScan (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice. Clin Gastroenterol Hepatol. 2015;13:27-36
Trépo E, Potthoff A, Pradat P, et al. Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol. 2011;55(1):38-44.
Trépo E, Pradat P, Potthoff A, et al. Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C. Hepatology. 2011;54(1):60-9.
Vallet-Pichard A, Mallet V, Pol S. Predictive value of FIB-4 versus fibrotest, APRI, FIBROINDEX and FORNS to noninvasively estimate fibrosis in hepatitis C. Hepatology 2008;47:762-763.
van der Poorten D, Kwok A, Lam T, et al. Twenty-year audit of percutaneous liver biopsy in a major Australian teaching hospital. Intern Med J 2006;36:692-699.
Vergniol J, Boursier J, Coutzac C et al. Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronichepatitis C. Hepatology. 2014 Jul;60(1):65-76.
Vergniol J, Foucher J, Terrebonne E, et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011;140:1970-1979, 1979 e1971-1973.
Verhaegh P, Bavalia R, Winkens B, et al. Noninvasive tests do not accurately differentiate nonalcoholic steatohepatitis from simple steatosis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:837-861.
Vidovic N, Lochowsky RS, Goldmann G, et al. Correlation of transient elastography with APRI and FIB-4 in a cohort of patients with congenital bleeding disorders and HCV or HCV/HIV coinfection. Haemophilia 2010;16:778-785.
Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol 2018;68:305-15.
Wang K, Lu X, Zhou H et al. Deep learning Radiomics of shear wave elastography significantly improved diagnostic performance for assessing liver fibrosis in chronic hepatitis B: a prospective multicentre study. Gut 2018. Epub ahead of print
Wai CT, Cheng CL, Wee A, et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006;26:666-672.
WHO. Guidelines for the screening care and treatment of persons with hepatitis c infection. 2014 ; appendix 3.
Wilson LE, Torbenson M, Astemborski J, et al. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology 2006;43:788-795.
Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology. 2010;51:454-62.Wong GL, Wong VW, Choi PC, et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther 2011;16:165-172.
Yu Y, Wang J, Ng CW, et al. Deep learning enables automated scoring of liver fibrosis stages. Sci Rep 2018;8:16016.
Xu X, Su Y, Song R et al. Performance of transient elastography assessing fibrosis of single hepatitis B virus infection: a systematic review and meta-analysis of a diagnostic test. Hepatol Int. 2015;9:558-66.
Zarski JP, Sturm N, Guechot J, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. Journal of hepatology 2012;56:55-62.
Ziol M, Handra-Luca A, Kettaneh A, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005;41:48-54
© 2020 by Mauss, et al.